Literature DB >> 33262066

Adoptive T cell therapy: Boosting the immune system to fight cancer.

Ernesto Leon1, Raghuveer Ranganathan2, Barbara Savoldo3.   

Abstract

Cellular therapies have shown increasing promise as a cancer treatment. Encouraging results against hematologic malignancies are paving the way to move into solid tumors. In this review, we will focus on T-cell therapies starting from tumor infiltrating lymphocytes (TILs) to optimized T-cell receptor-modified (TCR) cells and chimeric antigen receptor-modified T cells (CAR-Ts). We will discuss the positive preclinical and clinical findings of these approaches, along with some of the persisting barriers that need to be overcome to improve outcomes.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adoptive cell therapy; CAR-T cells; Cytolytic T cells (CTLs); Hematologic malignancies; T-cell receptor-modified (TCR) cells; Tumor infiltrating T cells (TILs)

Year:  2020        PMID: 33262066     DOI: 10.1016/j.smim.2020.101437

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  5 in total

1.  Targeting breast cancer with a combination of DNT and LAG3 checkpoint blockage and its mechanism.

Authors:  Miao Wang; Yuhan Wei; Yingrui Li; Hongzhong Li; Jiangtao Jin; Yuting Lu; Qin Li
Journal:  Immun Inflamm Dis       Date:  2022-08

2.  Engineering CAR-T cells to activate small-molecule drugs in situ.

Authors:  Thomas J Gardner; J Peter Lee; Christopher M Bourne; Dinali Wijewarnasuriya; Nihar Kinarivala; Keifer G Kurtz; Broderick C Corless; Megan M Dacek; Aaron Y Chang; George Mo; Kha M Nguyen; Renier J Brentjens; Derek S Tan; David A Scheinberg
Journal:  Nat Chem Biol       Date:  2021-12-30       Impact factor: 16.174

Review 3.  Sintilimab for the treatment of non-small cell lung cancer.

Authors:  Lin Zhang; Weihao Lin; Fengwei Tan; Ning Li; Qi Xue; Shugeng Gao; Yibo Gao; Jie He
Journal:  Biomark Res       Date:  2022-04-18

4.  Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma.

Authors:  Giacomo Oliveira; Kari Stromhaug; Susan Klaeger; Tomasz Kula; Dennie T Frederick; Phuong M Le; Juliet Forman; Teddy Huang; Shuqiang Li; Wandi Zhang; Qikai Xu; Nicoletta Cieri; Karl R Clauser; Sachet A Shukla; Donna Neuberg; Sune Justesen; Gavin MacBeath; Steven A Carr; Edward F Fritsch; Nir Hacohen; Moshe Sade-Feldman; Kenneth J Livak; Genevieve M Boland; Patrick A Ott; Derin B Keskin; Catherine J Wu
Journal:  Nature       Date:  2021-07-21       Impact factor: 69.504

Review 5.  Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.

Authors:  Cai Zhang; Yuan Hu; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2021-07-15       Impact factor: 22.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.